Research finds blocking ceramide production reduces colorectal cancer spread in mice — Evidence Review
Published in Science, by researchers from MIT, Harvard Medical School, Dana Farber Cancer Institute, University Hospital Essen, German Cancer Consortium
Researched by
— the AI search engine for science
Table of Contents
Researchers at MIT have identified a tissue repair pathway, driven by the protein YAP1 and influenced by ceramide lipid metabolism, that colorectal cancer cells exploit to metastasize—especially in the context of obesity. Related studies generally support the link between ceramide metabolism, cancer progression, and the role of metabolic reprogramming in metastasis.
- Multiple studies corroborate the importance of ceramide metabolism in colorectal cancer progression, with evidence that altered ceramide levels and their regulatory enzymes impact tumor growth, metastasis, and patient outcomes 1 3 4 5.
- The connection between lipid metabolic pathways, including YAP1 signaling, and metastatic potential is reinforced by research on metabolic reprogramming in cancer cells and the impact of high-fat diets 10.
- There is ongoing debate about whether ceramide acts primarily as a tumor suppressor or promoter, but several studies suggest that the context—such as enzyme expression, modification, and subtypes of ceramide—determines its impact on metastasis 12 13 15.
Study Overview and Key Findings
Colorectal cancer remains a leading cause of cancer mortality, largely due to its ability to metastasize to distant organs such as the liver. Despite advances in surgical and chemotherapeutic approaches, a substantial proportion of patients relapse with metastatic disease, and the molecular drivers behind this spread have proven elusive. This new study highlights a non-mutational mechanism—specifically the hijacking of a tissue repair program by tumor cells, facilitated by lipid metabolism and the YAP1 protein—that may explain how metastasis occurs and why obesity worsens outcomes. Importantly, the findings suggest a new avenue for therapeutic intervention by targeting enzymes involved in ceramide synthesis, rather than focusing solely on genetic mutations.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | MIT, Harvard Medical School, Dana Farber Cancer Institute, University Hospital Essen, German Cancer Consortium |
| Journal Name | Science |
| Authors | Swagata Goswami, Qiming Zhang, Abdullah Burak Yildiz, Upasana Das Adhikari, Akhouri Kishore Raghawan, Manon Bulliard, Sabhyata Sedhain, Odai Darawshi, Cigdem Elif Celik, Feyza Cansiz, Constantin P. Krempe, Jonas Rösler, Gabriele Allies, Sven W. Meckelmann, Chiashin Chi, Felix-Levin Hormann, Sven Heiles, Joseph Sedlak, Wesley Grace, George Eng, Ethan Reich, Chiara Alquati, Kevin J. Williams, Benjamin J. Read, Edrees H. Rashan, Zhixin Li, Anup Jnawali, Jose A. Ortiz, Chesta Jain, Charles A. Whittaker, Osman H. Yilmaz, Vikram Deshpande, Oliver J. Schmitz, Albert Sickmann, Autumn G. York, Douglas S. Kwon, Ulf Neumann, Maria Fedorova, Matthew G. Vander Heiden, Besim Ogretmen, Nilay S. Sethi, Alpaslan Tasdogan, Ömer H. Yilmaz |
| Population | Mice with colon cancer and patients with colorectal cancer |
| Methods | Animal Study |
| Outcome | YAP1 activity, ceramide production, and metastasis |
| Results | Blocking ceramide production reduced colon cancer spread in mice. |
Literature Review: Related Studies
To contextualize the new findings, we searched the Consensus database of over 200 million research papers using the following queries:
- ceramide production colorectal cancer spread
- colon cancer metastasis mechanisms
- blocking ceramide effects on tumor growth
Literature Review Table
| Topic | Key Findings |
|---|---|
| How does ceramide metabolism affect colorectal cancer progression and metastasis? | - Altered ceramide levels are observed in colorectal cancer tissues and are linked to cancer progression and metastasis 1 3 4 5 10. - Enzymes regulating ceramide synthesis and degradation, such as DEGS2 and ceramide synthases, modulate tumor growth and metastatic behavior 3 5 14. |
| What is the role of lipid metabolic reprogramming (including YAP1) in cancer metastasis? | - Metabolic reprogramming, including increased glycolysis and altered lipid metabolism via pathways like Glut3-YAP, promotes colorectal cancer metastasis and is influenced by dietary fats 7 10. - YAP1 activation is associated with increased metastatic potential and lower survival rates in colorectal cancer 10. |
| Can targeting ceramide pathways or enzymes reduce cancer spread or promote apoptosis? | - Inhibiting ceramide synthesis enzymes (e.g., CERS3, DEGS2) or enhancing ceramide signaling can suppress tumor growth and metastasis in preclinical models 5 11 14. - Ceramide analogues and inhibitors of ceramidases induce apoptosis in metastatic colon cancer cells without harming normal cells, suggesting a therapeutic window 11 12 13. |
How does ceramide metabolism affect colorectal cancer progression and metastasis?
Ceramide metabolism is frequently altered in colorectal cancer, with changes in ceramide levels and the activity of key enzymes contributing to tumor growth, the ability of cancer cells to invade new tissues, and resistance to therapy. The new study's findings that ceramide production enables a tissue repair program exploited by metastatic cells are consistent with this body of research, which highlights both increases and decreases in specific ceramide species as influential in disease progression.
- Studies show elevated levels of certain ceramide species (e.g., C16, C24) in colorectal tumor tissues and increased expression of ceramide synthase enzymes 1.
- M6A methylation of DEGS2, a ceramide-synthesizing enzyme, is implicated in colorectal cancer progression via regulation of ceramide synthesis 3.
- ECHS1-induced imbalance in ceramide glycosylation promotes colorectal cancer progression and can be partially reversed by inhibitors targeting downstream pathways 4.
- Microbial metabolites, such as riboflavin from Bacteroides species, can inhibit ceramide synthase 3 activity and delay colorectal cancer progression 5.
What is the role of lipid metabolic reprogramming (including YAP1) in cancer metastasis?
Metabolic reprogramming—particularly changes in lipid metabolism and the activation of signaling proteins like YAP1—has emerged as a key driver of colorectal cancer metastasis. The new study's identification of a YAP1-driven regenerative program aligns with research showing that metabolic shifts, influenced by diet or genetic alterations, facilitate the aggressive behavior of metastatic cells.
- Upregulation of glycolytic and lipid metabolic pathways, such as Glut3-YAP signaling, is associated with increased invasiveness and poor survival in metastatic colorectal cancer 10.
- Obesity and high-fat diets can drive the activation of these pathways, further enhancing metastatic potential 10.
- ACLY, another lipid metabolism enzyme, stabilizes CTNNB1 and promotes metastasis in colon cancer 7.
- Recent reviews emphasize the importance of understanding metabolic reprogramming for developing new therapeutics for metastatic colorectal cancer 6 8.
Can targeting ceramide pathways or enzymes reduce cancer spread or promote apoptosis?
Several studies suggest that manipulation of ceramide pathways—either by inhibiting specific biosynthetic enzymes or increasing ceramide levels—can reduce tumor growth and metastasis, often by inducing apoptosis in cancer cells. The new study’s observation that blocking ceramide production limits metastasis is supported by these findings, though the context-dependent role of ceramide (tumor suppressor vs. promoter) is complex.
- Ceramide analogues and ceramidase inhibitors selectively induce apoptosis in metastatic colon cancer cells, preventing tumor growth in preclinical models 11.
- Sphingolipid metabolism, particularly the balance between ceramide and sphingosine-1-phosphate, is critical in regulating cancer cell death and survival 12.
- Targeting specific ceramide synthases or trafficking pathways (e.g., CerS4, CERS3, DEGS2) modulates metastatic behavior and may open new therapeutic opportunities 5 13 14 15.
- Ceramide’s tumor-suppressive effects can be context-dependent, and both increases and decreases in ceramide synthesis have been linked to cancer progression or inhibition 13 15.
Future Research Questions
While the new study advances understanding of how ceramide metabolism and tissue repair pathways drive colorectal cancer metastasis, further research is needed to clarify the therapeutic potential and mechanisms involved. Key questions remain about the specificity, safety, and broader applicability of targeting ceramide pathways in cancer treatment.
| Research Question | Relevance |
|---|---|
| How does inhibiting specific ceramide-synthesizing enzymes affect metastasis in different colorectal cancer subtypes? | Subtype-specific responses may determine the efficacy and safety of targeting ceramide synthesis, as different enzymes and ceramide species are variably expressed in tumors 1 3 5. Further investigation could lead to more precise, personalized therapies. |
| What are the long-term effects of pharmacologically modulating ceramide levels in normal tissue versus cancer? | Ceramides are critical for normal cell function, so systemic modulation may have unintended effects. Understanding these risks is essential for developing safe cancer therapies 12 13. |
| How does dietary fat composition influence ceramide production and colorectal cancer progression? | The new study and others suggest that diet modulates ceramide metabolism and metastatic risk, but the effects of specific fatty acids or macronutrient profiles are not fully understood 5 10. |
| Can YAP1 or its downstream targets be effectively inhibited without disrupting normal tissue repair functions? | YAP1 is important for both tumor progression and normal tissue regeneration. Selective inhibition strategies are needed to minimize side effects and maximize therapeutic benefit 10. |
| What is the role of the gut microbiome in regulating ceramide metabolism and colorectal cancer metastasis? | Microbial metabolites can influence ceramide pathways and tumor behavior, suggesting that microbiome-targeted interventions may complement existing therapies 5 9. |